Scope and claim construction for US Patent 8,962,829 (morphic Form II of phosphonic acid ester; Compound 1)
US 8,962,829 is a US patent focused narrowly on (i) a specific morphic polymorph/crystal form (“Form II”) of a defined phosphonic acid-derived ester active (Compound 1), and (ii) the analytical fingerprints that prove that form (XRPD peak sets and DSC thermograms), plus (iii) a production workflow that drives crystallization into Form II (including magnesium tert-butoxide conversion and methanol crystallization, with seeding and specific purity thresholds). The enforceable claim boundaries are tight because most independent coverage turns on matching the defined crystalline identity and its specified impurity/purity attributes.
What is US Patent 8,962,829 and what does it claim?
US 8,962,829 claims a morphic Form II of a single, fully specified chemical entity:
Compound 1 = phosphonic acid,
[[ (S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]mono[3-(hexadecyloxy)propyl]ester]
The patent also claims (a) a method of preparing that morphic Form II and (b) compositions characterized by low levels of other forms/impurities.
Claim set map (by category)
A. Product-by-form identity (compound polymorph claims)
- Claim 1: Morphic Form II of Compound 1 (functional definition through “morphic Form II”).
- Claims 2-6: Form II tied to specific XRPD and DSC signatures:
- XRPD prominent peaks at ~2.81° and ~5.63° (2θ) (Claim 2).
- XRPD multi-peak sets from a long list; each peak expressed within (±0.2°) of selected values (Claim 3).
- XRPD “substantially similar” to specified figures (Claim 4).
- DSC “substantially similar” to specified figures (Claims 5-6).
- Claim 16: Specific DSC behavior with temperature markers (endotherm at ~41–43°C, overlapping endotherms at ~90 and ~95°C, and endotherm at ~196°C).
B. Product-by-manufacturing (process-derived product)
- Claim 7: Form II produced by recrystallization from methanol.
C. Method claims (making Form II)
- Claim 8: Method includes combining specified intermediates/starting materials with magnesium tert-butoxide and crystallizing from methanol.
- Claims 9-16: Claim 8 dependent refinements:
- Purity threshold: ≥ ~91% wt/wt Form II (Claim 9).
- XRPD peak requirement (Claim 10; dependent on Claim 8).
- XRPD multi-peak set requirement (Claim 11).
- XRPD “substantially similar” to specified figures (Claim 12).
- DSC “substantially similar” to specified figures (Claim 13).
- Seeding with phosphonic acid at ~0.5% / ~3% / ~7% wt/wt (Claim 14; seed can be Form II or Form I) (Claim 15).
- Additional DSC endpoint behavior (Claim 16).
D. Composition/quality control claims
- Claim 17: Composition containing < ~1.5% wt/wt of Form H, Form I, and/or amorphous forms.
- Claims 18-19: Composition impurity limits (Claim 18 references “less than about 2% wt/wt of any of the following compounds…” but the list is truncated in the provided claims text; Claim 19 limits total impurities to < ~2% wt/wt).
- Claims 20-22: A composition comprising Form II, Form I and Form H (Claim 20), plus distribution constraints:
- > ~90% wt/wt Form II (Claim 21)
- < ~10% wt/wt of Form I and Form H (Claim 22)
How is “morphic Form II” defined, and what does that do to claim scope?
The claims are built around objective analytical criteria rather than broad chemical genus language. Practically, “Form II” is treated as a distinct solid-state form that must be proven by XRPD and DSC.
XRPD-based definition narrows the infringement boundary
Key narrowing features:
- Peak positions: Claim 2 hard-codes prominent peaks at ~2.81° and ~5.63° (2θ).
- Peak list within tolerance: Claim 3 requires a two-or-more peak pattern selected from a fixed set, with each peak position within ±0.2°. This creates a “hit list” that can be engineered around by:
- shifting relative peak positions via measurement conditions (risk exists for disputes around instrument and conditions),
- preparing a related but distinct polymorph with non-matching peaks, or
- amorphizing/solvating into a non-matching phase.
- “Substantially similar” figure matching: Claims 4 and 12 tie the form to patterns that are “substantially similar” to specific figures. This is less rigid than the numeric peak list but still acts as a gate because the patent’s infringement theory would rely on matching the figure-defined fingerprint.
DSC-based definition adds a second lock
- “Substantially similar” DSC (Claims 5 and 6, also Claim 13) supports a second confirmatory dimension.
- Claim 16 provides stronger numeric anchor points at ~41–43°C, ~90°C and ~95°C, and ~196°C, which improves enforcement leverage against competitors who only meet XRPD.
Manufacturing-derived product claim is narrower than it sounds
- Claim 7 ties Form II to being produced by recrystallizing Compound 1 preparations from methanol. This can be a fallback theory where the competitor cannot be shown to have produced “Form II” directly but did produce it under that specific purification condition.
What product infringers are most at risk under US 8,962,829?
The patent’s highest practical risk concentration is on products that:
- Contain Compound 1 in Form II identity as proven by XRPD/DSC, and
- Meet the quality specifications for low Form H/Form I/amorphous content and low total impurities.
Infringement posture by claim type
- Claims 1-6 and 16: Direct risk to any supplier or marketer selling or using Form II as an ingredient, intermediate, or drug substance if XRPD/DSC fingerprints match.
- Claims 17-22: Direct risk to formulations or drug substance specifications that aim for high Form II content (Claims 21-22) while keeping Form I/Form H under <10% wt/wt and under <1.5% wt/wt for Form H/Form I/amorphous in the tighter claim (17).
Quality thresholds are meaningful because they force solid-state control
- < ~1.5% wt/wt Form H/Form I/amorphous (Claim 17) creates a measurable spec.
- > ~90% wt/wt Form II (Claim 21) and < ~10% Form I/Form H (Claim 22) create enforceable composition ranges.
What method-of-production steps are claimed, and how do they constrain infringement?
Claim 8 is the central method claim. The method includes:
- combining (S)-N1-[(2-hydroxy-3-triphenylmethoxy)propyl]cytosine (Compound 2),
- with P-[[[4-methylphenyl)sulfonyl]oxy]methyl]-, mono[3-(hexadecyloxy)propyl]ester, sodium salt (Compound 4),
- with magnesium tert-butoxide,
- using a suitable organic solvent, and
- crystallizing from methanol to obtain Form II.
Where competitors can create “design-around” surface area
The patent’s method constraints point to likely design-around levers:
- Avoid the specific base: claim 8 requires magnesium tert-butoxide.
- Avoid methanol crystallization as the final crystallization solvent (though Claim 7 still anchors methanol purification in a product-by-process claim).
- Avoid the specific seeding amounts and allowable seed forms:
- seeding at ~0.5%, ~3%, or ~7% wt/wt (Claim 14),
- seeding with seed that is Form II or Form I (Claim 15).
Even if a competitor makes the same polymorph by different chemistry or crystallization conditions, the numeric/analytical product claims may still capture them if the final solid is Form II by XRPD/DSC.
What does the claim language imply about “coverage” across intermediates, drug substance, and drug product?
This patent is primarily a solid-state polymorph patent. Depending on how “composition comprising” is practiced, coverage likely extends to:
- API/drug substance lots where polymorph purity is controlled,
- intermediate isolations where the polymorph identity is maintained, and
- formulated drug products where the drug substance is present as Form II with the claimed impurity/form distributions (Claims 17-22).
The claim set does not read like an excipient-specific formulation patent. It reads like a material spec patent.
What is the practical scope of each key claim (feature-by-feature)
Claim 1 (core product)
- “Morphic Form II” is the only defining element. Scope is limited by the specification’s definition of Form II, which the dependent claims effectively operationalize via XRPD/DSC.
Claim 2 (XRPD prominent peaks)
- Requires XRPD peaks at ~2.81° and ~5.63° (2θ). This is a narrow but strong objective anchor.
Claim 3 (XRPD multi-peak selection set)
- Requires:
- “two or more peaks”
- each peak must be within ±0.2° of a value selected from a fixed list that includes 2.81, 5.63, 11.30, …, 29.61.
- This claim can be used to argue equivalence of measurement datasets that still land inside the acceptable windows.
Claim 4 (XRPD “substantially similar” to figures)
- Covers datasets that match the figure pattern sufficiently to be argued as substantially similar even if not all numeric peaks are reproduced perfectly.
Claims 5-6 and Claim 16 (DSC anchors)
- Substantially similar DSC thermograms map the form even where XRPD might be harder to reproduce due to sample prep.
Claim 7 (methanol recrystallization product-by-process)
- Adds a method-derived gate. If a party can show they produced Form II by a different purification solvent system, they may try to defeat this claim, but not necessarily Claims 1-6/16 if XRPD/DSC match.
Claim 8 (method synthesis plus crystallization)
- Combines defined starting materials with magnesium tert-butoxide and crystallizes from methanol.
- Enforced through step-by-step evidence in manufacturing or process documentation.
Claim 9 (purity)
- Requires Form II purity ≥ ~91% wt/wt. This ties solid-state form control directly to infringement.
Claims 10-13 (XRPD/DSC confirmations within the method)
- Reinforces Claim 8 result criteria with analytical proof.
Claims 14-15 (seeding)
- Adds a process parameter that can be a clear differentiator, though again product claims remain a parallel pathway.
Claims 17-22 (composition quality)
- Enforceable ranges for polymorph distribution and impurity content.
How strong is the patent estate likely to be on infringement and litigation leverage?
Based on structure and claim architecture alone, US 8,962,829 has features that generally increase enforcement leverage for polymorph patents:
- Multiple independent ways to “prove Form II” (XRPD numeric peaks, multi-peak lists, and DSC thermograms).
- Tight quantitative quality constraints that map to standard release testing.
- A method claim that includes both reagent/chemical steps and a crystallization endpoint in methanol.
The downside is that the patent is also tightly scoped to Form II identity. If competitors can reliably switch to a different polymorph (or amorphous/solvated form) whose XRPD/DSC fingerprints do not match the specified peak positions and DSC markers, they can potentially avoid direct product infringement.
US patent landscape context: what else typically surrounds polymorph patents like this?
For a compound-specific polymorph patent, the surrounding landscape usually contains:
- earlier patents covering the chemical entity (Compound 1),
- earlier or later patents covering other polymorphs (Form I, Form H, amorphous forms) including their XRPD/DSC fingerprints,
- patents covering manufacturing routes to the API (chemical synthesis and salt formation), and
- later patents covering formulation or solid-state stabilization approaches.
This particular patent’s claims heavily imply that other forms (Form I and Form H) exist in the same family or adjacent families, because the composition claims quantify “Form H, Form I and/or amorphous forms” against Form II.
Key comparison matrix: where the claims draw the line
| Issue |
What US 8,962,829 requires |
Practical litigation question |
| Solid-state identity |
Form II proven by XRPD and/or DSC |
Does the accused material match the peak list and DSC markers? |
| XRPD |
Peak ~2.81° and ~5.63° (2θ), plus multi-peak set within ±0.2° |
Which dataset and conditions were used, and do the peaks fall within windows? |
| DSC |
Endotherm anchors around ~41–43°C, ~90 and ~95°C, and ~196°C |
Does the DSC trace show the same thermal behavior? |
| Process conditions |
magnesium tert-butoxide + methanol crystallization |
Was the method followed, and is it documented? |
| Seeding |
0.5%/3%/7% wt/wt seed, Form II or Form I |
Was seeding used in those ranges? |
| Polymorph purity |
<1.5% Form H/Form I/amorphous (Claim 17); >90% Form II (Claim 21) |
Do commercial specs satisfy these thresholds? |
| Impurities |
<2% wt/wt total impurities (Claim 19); additional compound-specific limits (Claim 18) |
Are impurity profiles within the claimed caps? |
Key takeaways
- US 8,962,829 is a polymorph-focused patent that claims Compound 1 in morphic Form II, with identity established through XRPD peak positions and DSC thermogram markers.
- The broadest product coverage (Claims 1 and 20) is still effectively bounded by the analytical definition of “Form II,” strengthened by dependent XRPD/DSC claims.
- The enforceable method coverage (Claim 8) is driven by magnesium tert-butoxide chemistry and methanol crystallization, with further narrowing through seeding and purity requirements.
- Composition claims turn solid-state control into measurable legal thresholds: <1.5% Form H/Form I/amorphous and >90% Form II with <10% Form I/Form H.
FAQs
1. What analytical methods would be central to proving infringement of US 8,962,829?
XRPD peak presence/positions within the specified tolerances and DSC thermograms matching the claimed endotherm pattern.
2. Can a competitor avoid US 8,962,829 by using a different solvent for crystallization?
They may avoid the method claim if crystallization is not from methanol and seeding conditions differ, but product claims can still be triggered if the final solid is the same Form II by XRPD/DSC.
3. Do the claims require absolute crystallinity or allow amorphous content?
They define explicit limits for amorphous and other forms in composition claims (Claims 17 and 22), but the core Form II product claims target the Form II material identity.
4. How do the XRPD tolerance windows affect design-around strategies?
The multi-peak requirement in Claim 3 uses fixed peak values with ±0.2° windows, so shifting peak positions outside those windows is the primary analytical path to non-infringement.
5. What is the highest-value claim for enforcement against drug substance suppliers?
Claims 1-3 and 16 are the most direct because they tie product infringement to objective XRPD/DSC identity of Form II of Compound 1, while Claims 17-22 add strong leverage via commercial-quality thresholds.
